The independent clinical study was conducted by Jed Kaminetsky, M.D., Medical Director at
The top line results of the interim analysis from 21 men show:
PREBOOST® is a new, proprietary over-the-counter (OTC) male genital desensitizer used for the treatment of PE. Unlike currently available OTC anesthetic sprays using lidocaine or gels using benzocaine, PREBOOST® is an individually packaged wipe containing 4% benzocaine, which allows for direct and precise application of the same dosage each time.
“Our interim results in men with PE show that PREBOOST® appears to prolong time to ejaculation, supporting the clinical validity of PREBOOST® for the management of PE,” said Mitchell Steiner, M.D. President and Chief Executive Officer of
“Our plan is to launch PREBOOST® in the US later this quarter through digital and social media marketing,” said Shiao Zhu, Vice President of Marketing of
For more information about PREBOOST®, please visit www.preboost.com.
About Premature Ejaculation (PE):
The Company plans to implement a sampling program targeting urologists, co-promoting with a marketing partner, introducing the product through Walmart, CVS, Walgreens and other OTC distribution outlets, optimizing its internet ecommerce capabilities and digital marketing via www.preboost.com, as well as through out-licensing opportunities for markets outside the U.S.
More information about the
"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:
Contact: Kevin Gilbert 312-366-2633
Press Release Kari Sharp